Exec Chat: Cognetivity’s Simple Brain Test Could Unlock Trillions In Health Care Savings
Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.
You may also be interested in...
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
Find a problem and develop the solution for it: so goes the accepted wisdom for successful health care technology adoption. But as Cognetivity Neurosciences CEO Sina Habibi demonstrates, the reverse can also provide a very valid business pathway.
The butterfly effect is an elegant analogy to describe the seemingly unpredictable and far-reaching implications of a relatively small and inconsequential event. The FDA’s approval of Aduhelm is not so much a butterfly gently flapping its wings, but rather a sonic boom emanating from a jet engine. Most immediately, it provides a new therapeutic option for millions of patients in dire need of hope, vindicating Biogen’s faith with a revenue stream running into many billions of dollars. Longer-term the reverberations may be felt across the entire industry, throwing into question the evidentiary requirement for drug development.